256 related articles for article (PubMed ID: 24198417)
21. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis.
Hoffmann HH; Kunz A; Simon VA; Palese P; Shaw ML
Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5777-82. PubMed ID: 21436031
[TBL] [Abstract][Full Text] [Related]
22. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses.
Rojek JM; Pasqual G; Sanchez AB; Nguyen NT; de la Torre JC; Kunz S
J Virol; 2010 Jan; 84(1):573-84. PubMed ID: 19846507
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs.
Herring S; Oda JM; Wagoner J; Kirchmeier D; O'Connor A; Nelson EA; Huang Q; Liang Y; DeWald LE; Johansen LM; Glass PJ; Olinger GG; Ianevski A; Aittokallio T; Paine MF; Fink SL; White JM; Polyak SJ
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468464
[TBL] [Abstract][Full Text] [Related]
24. Lifecycle modelling systems support inosine monophosphate dehydrogenase (IMPDH) as a pro-viral factor and antiviral target for New World arenaviruses.
Dunham EC; Leske A; Shifflett K; Watt A; Feldmann H; Hoenen T; Groseth A
Antiviral Res; 2018 Sep; 157():140-150. PubMed ID: 30031760
[TBL] [Abstract][Full Text] [Related]
25. DDX3 suppresses type I interferons and favors viral replication during Arenavirus infection.
Loureiro ME; Zorzetto-Fernandes AL; Radoshitzky S; Chi X; Dallari S; Marooki N; Lèger P; Foscaldi S; Harjono V; Sharma S; Zid BM; López N; de la Torre JC; Bavari S; Zúñiga E
PLoS Pathog; 2018 Jul; 14(7):e1007125. PubMed ID: 30001425
[TBL] [Abstract][Full Text] [Related]
26. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.
Martinez-Sobrido L; de la Torre JC
Expert Rev Vaccines; 2016 Sep; 15(9):1113-21. PubMed ID: 27118328
[TBL] [Abstract][Full Text] [Related]
27. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses.
Lee AM; Rojek JM; Spiropoulou CF; Gundersen AT; Jin W; Shaginian A; York J; Nunberg JH; Boger DL; Oldstone MB; Kunz S
J Biol Chem; 2008 Jul; 283(27):18734-42. PubMed ID: 18474596
[TBL] [Abstract][Full Text] [Related]
28. Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses.
Westover JB; Sefing EJ; Bailey KW; Van Wettere AJ; Jung KH; Dagley A; Wandersee L; Downs B; Smee DF; Furuta Y; Bray M; Gowen BB
Antiviral Res; 2016 Feb; 126():62-8. PubMed ID: 26711718
[TBL] [Abstract][Full Text] [Related]
29. Biological Characterization of Conserved Residues within the Cytoplasmic Tail of the Pichinde Arenaviral Glycoprotein Subunit 2 (GP2).
Shao J; Huang Q; Liu X; Di D; Dileepan M; Brisse M; Ly H; Liang Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462569
[TBL] [Abstract][Full Text] [Related]
30. Novel drug discovery approaches for treating arenavirus infections.
Pasquato A; Kunz S
Expert Opin Drug Discov; 2016; 11(4):383-93. PubMed ID: 26882218
[TBL] [Abstract][Full Text] [Related]
31. Tangeretin, an extract from Citrus peels, blocks cellular entry of arenaviruses that cause viral hemorrhagic fever.
Tang K; He S; Zhang X; Guo J; Chen Q; Yan F; Banadyga L; Zhu W; Qiu X; Guo Y
Antiviral Res; 2018 Dec; 160():87-93. PubMed ID: 30339847
[TBL] [Abstract][Full Text] [Related]
32. Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy.
Damonte EB; Coto CE
Adv Virus Res; 2002; 58():125-55. PubMed ID: 12205778
[No Abstract] [Full Text] [Related]
33. The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.
Iwasaki M; Cubitt B; Sullivan BM; de la Torre JC
J Virol; 2016 Jan; 90(6):3187-97. PubMed ID: 26739049
[TBL] [Abstract][Full Text] [Related]
34. Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro.
Kim YJ; Cubitt B; Cai Y; Kuhn JH; Vitt D; Kohlhof H; de la Torre JC
Viruses; 2020 Jul; 12(8):. PubMed ID: 32751087
[TBL] [Abstract][Full Text] [Related]
35. Multifunctional nature of the arenavirus RING finger protein Z.
Fehling SK; Lennartz F; Strecker T
Viruses; 2012 Nov; 4(11):2973-3011. PubMed ID: 23202512
[TBL] [Abstract][Full Text] [Related]
36. Current drug discovery strategies against arenavirus infections.
Pasquato A; Burri DJ; Kunz S
Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1297-309. PubMed ID: 23241187
[TBL] [Abstract][Full Text] [Related]
37. Arenaviruses and hantaviruses: from epidemiology and genomics to antivirals.
Charrel RN; Coutard B; Baronti C; Canard B; Nougairede A; Frangeul A; Morin B; Jamal S; Schmidt CL; Hilgenfeld R; Klempa B; de Lamballerie X
Antiviral Res; 2011 May; 90(2):102-14. PubMed ID: 21356244
[TBL] [Abstract][Full Text] [Related]
38. Novel antiviral strategies to combat human Arenavirus infections.
Kunz S; de la Torre JC
Curr Mol Med; 2005 Dec; 5(8):735-51. PubMed ID: 16375709
[TBL] [Abstract][Full Text] [Related]
39. Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.
Cheng BYH; Nogales A; de la Torre JC; Martínez-Sobrido L
Virology; 2017 Jan; 501():35-46. PubMed ID: 27855284
[TBL] [Abstract][Full Text] [Related]
40. A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding.
Capul AA; de la Torre JC
Virology; 2008 Dec; 382(1):107-14. PubMed ID: 18929379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
